HLA-A and esophageal squamous cell carcinoma: Our phase I clinical trial comprising a combination therapy of multiple-peptide vaccine and CRT in patients with HLA-A*2402 positive unresectable ESCC proceeded with satisfactory safety levels in all the patients.